Omnicell Introduces OmniSphere Platform, Stock to Gain
| HAE Stock | USD 73.35 1.89 2.51% |
About 62% of Haemonetics' investor base is looking to short. The analysis of overall sentiment of trading Haemonetics stock suggests that many investors are alarmed at this time. The current market sentiment, together with Haemonetics' historical and current headlines, can help investors time the market. In addition, many technical investors use Haemonetics stock news signals to limit their universe of possible portfolio assets.
Haemonetics |
Omnicell introduces OmniSphere. Additionally, the company showcases a full portfolio of outcomes-centric solutions at the ASHP Midyear 2024.
Read at finance.yahoo.com
 |
Haemonetics Fundamental Analysis
We analyze Haemonetics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Haemonetics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Haemonetics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Asset
Return On Asset Comparative Analysis
Haemonetics is currently under evaluation in return on asset category among its peers. Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Haemonetics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Haemonetics stock to make a market-neutral strategy. Peer analysis of Haemonetics could also be used in its relative valuation, which is a method of valuing Haemonetics by comparing valuation metrics with similar companies.
Peers
Haemonetics Related Equities
| AKYA | Akoya Biosciences | 6.29 | ||||
| NVST | Envista Holdings | 2.43 | ||||
| HOLX | Hologic | 1.17 | ||||
| ANGO | AngioDynamics | 1.01 | ||||
| WST | West Pharmaceutical | 0.92 | ||||
| MMSI | Merit Medical | 0.32 | ||||
| ALC | Alcon AG | 0.27 | ||||
| ICUI | ICU Medical | 0.08 | ||||
| COO | Cooper Companies, | 0.18 | ||||
| RMD | ResMed | 0.19 | ||||
| ATRC | AtriCure | 0.33 | ||||
| ATR | AptarGroup | 0.48 | ||||
| TFX | Teleflex Incorporated | 0.93 |
Complementary Tools for Haemonetics Stock analysis
When running Haemonetics' price analysis, check to measure Haemonetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Haemonetics is operating at the current time. Most of Haemonetics' value examination focuses on studying past and present price action to predict the probability of Haemonetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Haemonetics' price. Additionally, you may evaluate how the addition of Haemonetics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |